

**Predstavljanje prijedloga projekata
akronima *CAPRI2010* i *TransMedRi*
prijavljenih na natječaje FP7-REGPOT-2008-1,
odnosno FP7-REGPOT-2009-1**

**Prof.dr. Stipan Jonjić
Medicinski fakultet Sveučilišta u Rijeci**

***Radionica o novim FP7 REGPOT natječajima
Zagreb, 2. srpnja 2009.***

Zahvala

FP7-REGPOT-2008-1

Tihana Lenac Roviš
Kerol Bartolović
Christian Kleinhammer

FP7-REGPOT-2009-1

Siniša Volarević
Maja Abram / Tomislav Rukavina
Astrid Krmpotić
Bojan Polić
Alan Šustić, dekan



Ani Gerbin
*Administrativna i
financijska pitanja*




Borimo li se zaista dovoljno za međunarodne projekte i koliko smo stvarno uspješni?

Kako **realno** stojimo u Hrvatskoj u pogledu razvijenosti znanosti?

- **slaba apsorpcijska sposobnost naše znanosti**
- **usitnjenost**
- **nedovoljna umreženost**
- **nefokusiranost**
- **neselektivnost**
- **senzacionalizam**
- **nespremnost institucija (sveučilišta i fakulteta) da na sebe preuzmu odgovornost za reforme**

Trenutno stanje znanosti – usporedna analiza **biomedicinskih** **publikacija**


2003 - 2008. god.



Izvor: PubMed


Trenutno stanje znanosti – Sveučilište u Rijeci

Broj i čimbenik utjecaja biomedicinskih članaka
Sveučilište u Rijeci, 2008. g.



Izvor: ISI Web of Knowledge

Što čini kvalitetno visoko učilište?



1. Istraživačko sveučilište
2. Zajamčen razvoj kadrova
3. Zajamčen uspjeh

Razvoj vrhunskih kadrova

Ne otkrivati toplu vodu, već slijediti primjere uspješnih!

- **Pozitivni odabir na svim razinama**
- **Ciljana edukacija na uglednim sveučilištima**
- **Bolje povezivanje primijenjenih i temeljnih znanosti**
- **Umrežavanje naših znanstvenika u međunarodnu znanstvenu i akademsku zajednicu kroz projekte (FP7, NIH)**
- **Podizanje kriterija izbora i unaprjeđivanja u znanstvena i nastavna zvanja i izbor rukovodećih kadrova**

Možemo zaključiti...

- Nerazvijenost visokoškolskog i znanstvenog sustava **najveća je prepreka** uspjehu Hrvatske u europskom istraživačkom i obrazovnom prostoru
- Uz strukturne i druge razvojne promjene na sveučilištima **svi moramo napraviti više** na mobilizaciji (edukaciji) kadrova za moderno sveučilište i društvo općenito
- Promjene koje nas očekuju neće biti lagane, ali se moraju **temeljiti na izvrsnosti** znanstvenog, stručnog i nastavnog rada
- Nema mjesta pesimizmu iako bi bilo pogrešno i opasno stvarati privid da nema problema.
- **Moramo se izboriti ne samo za više kriterije već i za bolji status znanosti i struke jer ćemo jedino tako razviti kvalitetnu znanost.**

The Center for Antibody Production Rijeka: Upgrading the Central Research and Service Infrastructure for the South Eastern Region of Europe


CAPRI2010

- **Natječaj:** FP7-REGPOT-2008-1
- **Rok za prijavu:** 14.03.2008.
- **Zatraženi iznos:** EUR 712.700
- **Trajanje projekta:** 36 mjeseci
- **Primitak ESR-a:** 19.06.2008.
- **Broj bodova:** 14,5/15
- **Poziv na pregovore:**
10.07.2008.
- **Početak projekta:** 01.03.2009.
- **Odobreni iznos:** EUR 619.770



Iz sažetka prijedloga projekta **CAPRI2010**

The Center for Proteomics was established at the Medical Faculty, University of Rijeka in 2006 **with focus on monoclonal antibody (mAb) development** for cutting-edge applications including proteome analysis. ... The Center has now several hundred hybridoma cell lines at its disposal secreting mAbs to a large variety of target proteins. This collection will soon be made available to the scientific community. ... Thus, the Center is strategically positioned to serve as a **key resource for basic and clinical scientists in the Region and an important resource to the European scientific community.**



1st paragraph – presenting yourself

Iz sažetka prijedloga projekta **CAPRI2010**

The key activities of CAPRI2010 consist in the establishment of new scientific collaboration in mAb development and application, e.g. in proteome analysis. Through the support intended by the REGPOT-2008-1 call, the entire region will benefit from the activities of the Center through **(1) upgrading the infrastructural resources and (2) mobilizing human resources by providing special training**. The Center is unique and will therefore optimally serve the development of research and technological potential in the South Eastern Europe through aggregation of knowledge and resources, thus enhancing the capacity and competitiveness of these countries to participate and contribute to future EU research projects.



2nd paragraph – describing the objectives, strategy and expected impacts

CAPRI2010

Section 1. Scientific and/or technical quality

1.1. Concept and objectives

The CAPRI2010 project will improve the status of the Center for Proteomics by:

- upgrading its existing S&T potential (establishment of complete work-flow line)
- mobilizing human resources
- broadening and tightening the already prominent strategic partnerships

It will add a significant contribution to the regional development through:

- raising the competitiveness of the human research potential in the region
- development of the European Research Area as a whole
- strengthening the dissemination of the scientific information and research results
- facilitation of the communication on the regional and European levels

CAPRI2010

Section 1. Scientific and/or technical quality

1.1. a) Scientific and technological capacity of the Center for Proteomics (*strengths*)

GRANT / COLLABORATORS	ACHIEVEMENT / STATUS
Croatian Ministry of Science, Education and Sports Grant, JEZGRA 17	The Center established 02.03.2006 / Finished
EU-FP6-2002-INCO-WBC/SSA-3 Grant, Contract no: INCO-026278, CAPRI / Max von Pettenkofer Institute, Munich, University of Mostar	mAb production established / In progress till June 2008
FP6 Marie Curie Research Training Networks Grant, Contract No: MRTN-CT-2005 – 019248 / Medizinische Universität Wien	Joint publications Two-way secondments organized / In progress till December 2009
Unity through Knowledge Fund (UKF), Contract No: 08/07 / Ohio State University, Columbus	Started in December 2007 / In progress till December 2010
National Foundation for Science, Higher Education and Technological development of the Republic of Croatia, Contract No: 04/16 / Max von Pettenkofer Institute, Munich	Starting in March 2008

A list of collaborators of the Center for Proteomics

No.	COLLABORATOR	INSTITUTION	TOPIC	ACHIEVEMENTS
1	Prof. Juergen Haas	Max von Pettenkofer Institute, Munich	a) develop recombinant fusion protein b) mAbs to entire VZV proteins	a) completed b) almost completed
2	Prof. Ulrich Koszinowski	Max von Pettenkofer Institute, Munich	Development of mAbs to viral immunoevasins to MHC I and NKG2d ligands	J. Exp. Med. 190: 1285-1295, 1999; Nat. Immunol. 3:529-35, 2002; J.Virol. 82:2056, 2008; J.Virol. 81: 13825, 2007
3	Prof. Filip Culo	Medical Faculty, University of Mostar	Education of Ph.D. students, lab engineers and technicians	Education of two Ph.D. students and a lab technician
4	Prof. Hartmut Hengel	Heinrich-Heine University, Duesseldorf	mAbs against CMV proteins on the surface of infected cells	J. Exp.Med.201 211-220; 2005 J. Virol.79 (2005) 2920-30; J. Exp.Med. 203 (2006) 1843-50
5	Prof. Martin Messerle	Medical School, Hannover	mAbs to sets of MCMV and HCMV	In progress
6	Prof. William J Britt	University of Alabama , Birmingham	Focus on CNS and viral proteins involved in the pathogenesis of prenatal CMV infection	J. Exp. Med. 205(2) 423-35, 2008
7	Dr. Sebastian Voigt	Robert Koch-Institute, Berlin	mAbs against viral chemokines and cytokines	In progress
8	Dr. Joanne Trgovcich	Ohio State University, Columbus	Reveal specific mechanisms by which herpesviruses cause disease	mAbs to HCMV and MCMV antigens - in progress
9	Prof. Sinisa Volarevic	Medical Faculty, University of Rijeka	mAbs to ribosomal proteins	In progress

A list of collaborators of the Center for Proteomics

No.	COLLABORATOR	INSTITUTION	TOPIC	ACHIEVEMENTS
10	Prof. Helmut E. Meyer	Ruhr-Universität Bochum, Medizinisches Proteom-Center	mAbs for analysis of pancreatic tumor	Completed
11	Dr. Tvrtko Smital	Ruder Boskovic Institute, Zagreb	mAbs to ABC transport proteins for studies in ecotoxicology	In progress
12	Prof. Ana Marušić	Medical Faculty Zagreb	mAbs to glycosfingolipids	In progress
13	Dr. Renata Mazuran	Institute of Immunology, Zagreb	Development of tests for neurovirulence of viral vaccines on an animal virus model	In progress
14	Prof. Ofer Mandelboim	The Hebrew University Jerusalem	mAb to cell surface markers on mouse and human NK cells	Altogether 18 new mAbs against NK receptors and their ligands
15	Prof. Mathias Mueller	Veterinaermedizinische Universitaet Wien	mAbs to Jak-Stat	J. Immunol. 175(6):4000-4008, 2005
16	Dr. Alberto Visioli	StemGen, Milan	mAbs to neuro-stem cells	completed
17	Dr. David Margulies	Laboratory of Immunology, NIAID, Maryland	Generation of viral MHC I like proteins for studies in structural biology	J Biol Chem. 282(48):35247-58, 2007

CAPRI2010

Section 1. Scientific and/or technical quality

Detailed scientific and technological objectives of CAPRI2010

- **Objective 1:** *Upgrading the existing technological capacities*
- **Objective 2:** *Recruitment of research personnel who will optimize the Center's workflow and disseminate its potential*
- **Objective 3:** *Facilitation of knowledge transfer*
- **Objective 4:** *Exchange of know-how and experience*
- **Objective 5:** *Increasing the visibility of the Center for Proteomics*

“Razbijeni” na Radne pakete (Work Packages)

CAPRI2010

Section 1. Scientific and/or technical quality

Detailed scientific and technological objectives of CAPRI2010

Example: Objective 3: *Facilitation of knowledge transfer*


Table 4. Summary of techniques that will be introduced at workshops organized by the Center for Proteomics.

Technology of generating mAbs	Protein preparation
Immunization of mice with the protein of interest	Bacterial growth/lysis Bacterial protein expression
Fusion of murine spleen cells to the myeloma cell line SP2/O	Protein electrophoresis
Culturing the hybridoma cells	Gel/blot imaging
Screening of hybridoma supernatants by ELISA assay	Protein purification (liquid chromatography / affinity, gel filtration)
Cloning of hybridoma colonies	Protein analysis (characterization)
Screening for positive clones by various techniques (ELISA, FACS, Western Blot, Immunoprecipitation, Immunofluorescence, etc.)	Western blot (WB) /immunoprecipitation (IP) /biotinylation
RNA/DNA analysis	Immunofluorescence (using the fluorescent and confocal studies)
Bacterial growth/DNA isolation	Immunohistochemistry (using the paraffin and frozen sections)
Isolation of RNA	ELISA assay
Northern blot/Southern blot	Flow cytometry (FACS) analysis (intracellular, surface staining)

CAPRI2010

Section 1. Scientific and/or technical quality

iv) A graphical presentation of the components and their interdependencies (Pert diagram)



KOMENTARI EVALUATORA

Kriterij 1: Scientific & Technological Excellence

(max: 5 bodova; prolaz: 3/5)

- Centar za proteomiku je entitet s visokom znanstvenom izvrsnošću
- Glavni cilj projekta je dovesti na višu razinu kapacitete za produkciju monoklonskih protutijela i proteomiku
- Zadaci unutar svakog cilja su dobro definirani
- Radni paketi su usklađeni s mjerama zadanim od strane EK
- Izvrsna SWOT analiza
- Ekspertiza znanstvenika angažiranih na projektu
- Iskustvo na FP6 projektima
- Potencijalna opasnost da produkcija monokl. protutijela postane sržna aktivnost (što već nude komercijalne kompanije) pada u drugi plan s obzirom da novi planovi (uključujući produkciju fuzijskih proteina) Centru daju novu dimenziju

Ocjena: 5

CAPRI2010

Section 2. Implementation


2.1 Management and organisational structure and procedures

Coworker	Year 1				Year 2				Year 3			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
RI 1	WP1				WP2 - MAb development team							
RI 2	WP1				WP2 - Protein expression team							
RI 3	WP1-5											
LE 1	WP1				WP2 - MAb development collaboration projects 1-4							
LE 2	WP1				WP2 - MAb development collaboration projects 1-4							
LE 3	WP1				WP2 - Protein expression and mAb production upscaling for collaborative projects							
LE 4	WP1				WP2 - Protein expression and mAb production upscaling for collaborative projects							
AA	WP3, WP4, WP5, WP6											
PM	WP6											
Legend:	WP1: Upgrading technological abilities WP2: Recruitment of research personnel for workflow optimization WP3: Organizing workshops, seminars and conferences WP4: Exchange of know-how in mAb development and protein expression/analysis WP5: Dissemination activities WP6: Project management											
RI = Research Investigator												
LE = Lab Engineer												
AA = Administrative Assistant												
PM = Project manager												

CAPRI2010

Section 2. Implementation

2.1 Management and organisational structure and procedures



KOMENTARI EVALUATORA

Kriterij 2: Implementation & Management

(max: 5 bodova; prolaz: 3/5)

- **Pertov dijagram kao i menadžerska struktura su adekvatno i jasno razrađeni**
- **Mali nedostatak: većina znanstvenika će samo djelomice raditi na ovom projektu, što bi moglo dovesti do problema u upravljanju vremenom**
- **Koordinacija projekta uključuje nekoliko iznimno kvalificiranih znanstvenika s Fakulteta, o čemu svjedoče impresivne liste publikacija u vrhunski rangiranim časopisima u području imunologije**
- **Ekspertiza cijelog tima je dobro usklađena s radnim planom**
- **Budžet je vrlo dobro izbalansiran i usklađen**

Ocjena: 4,5

CAPRI2010

Section 3. Impact

- **Važno: Compliance with the expected impacts listed in the Work programme:**

- *Upgrading the RTD capacity and capability*
- *Better integration of the Center for Proteomics, Medical Faculty, University of Rijeka in the European Research Area as a whole*
- *Contribution to regional capacity building*
- *Improvement of the potential of the Center for Proteomics to participate in FP7 projects*



Opisati na koji način će se učinci projekta poklapati s učincima navedenim u Radnom programu

KOMENTARI EVALUATORA

Kriterij 3: Potential impact through use of project results

(max: 5 bodova; prolaz: 3/5)

- Ovaj projekt imat će visok učinak ne samo u Jugoistočnoj, već u cijeloj Europi, a posebno za Medicinski fakultet Sveučilišta u Rijeci
- Trebala bi biti razmotrena mogućnost “spinning out”-a tehnologije
- ERA je ovdje već prisutna kroz FP6 i druge projekte
- Diseminacijski plan je kvalitetan
- **Zaštita intelektualnih prava vlasništva (IPR) se ne spominje**

Ocjena: 5

Upgrading capacities for research in translational medicine at the Faculty of Medicine University of Rijeka


TransMedRi

- **Natječaj:** FP7-REGPOT-2009-1
- **Rok za prijavu:** 13.02.2009.
- **Zatraženi iznos:** EUR 3.508.404
- **Trajanje projekta:** 36 mjeseci
- **Koordinator:** Prof.dr. Bojan Polić, prodekan za znanost
- **Primitak ESR-a:** 26.05.2009.
- **Broj bodova:** 13,5/15



Iz sažetka prijedloga projekta TransMedRi


One of the major impediments for development of the biomedical research at the University of Rijeka has been the **lack of a competitive research environment**. ... Because of the limited internal resources, most of the training of the young investigators has been accomplished in the laboratories of Western countries. Although this tradition has proven to be beneficial, it has led to loss of promising scientists to faculty positions and slowed the development of a modern biomedical research. Furthermore, **translational research** has not been the traditional area of research in Croatia. ... However, it is of great importance to stress that the **expansion of clinical research activities is still lagging behind basic research**.



1st paragraph – identifying weaknesses

Iz sažetka prijedloga projekta TransMedRi

The Faculty of Medicine (MEDRI) has already **well-developed programs in life sciences, a respectable infrastructure, and ongoing international collaboration**. The following steps in research capacity building are to further strengthen the collaboration between investigators at MEDRI and the EU countries, organize and develop formal training programmes for investigators and implement an efficient program of research capacity building with **emphasis on the translational medicine in cancer and infectious diseases**. Thus, several activities are proposed to synchronize **training of researchers** with efforts to **upgrade and establish** research facilities to be used by several research groups and departments. The proposed activities should ultimately enable MEDRI to better integrate into the ERA.



2nd paragraph – showing strengths, describing the objectives, strategy and expected impacts

TransMedRi

Section 1. Scientific and/or technical quality

1.1. Concept and objectives

SWOT ANALYSIS

Strengths

1. **Competitive research groups** and departments at the Faculty of Medicine University of Rijeka relevant to this proposal
2. Established **international research collaboration**
3. Excellent scientific **reputation at national level**
4. Existing **research infrastructure** including core facilities
5. **Strategic Action plan** aimed to upgrade research capacity

TransMedRi

Section 1. Scientific and/or technical quality

Strength 1: Competitive research groups and departments at the Faculty of Medicine University of Rijeka relevant to this proposal:


Developmental and tumor biology

Viral immunosurveillance and pathogenesis

Bacterial pathogenesis

Immunology of reproduction

Cell physiology



TransMedRi

Strength 2: Established international research collaboration

D. Rukavina & 21 consortium members
EU FP6 NoE

S. Jonjić & 10 consortium members
EU FP6 Marie Curie Research Training Networks

B. Polić & 27 consortium members
EU FP6 CA

T. Frančičković & 7 consortium members
EU FP6 STREP

S. Volarević
SNSF-SCOPES

S. Volarević & Z. Dembić
University of Oslo
Unity through Knowledge Fund (UKF)

S. Jonjić & W. J. Britt
University of Alabama,
Birmingham
RO1, National Institutes of Health (NIH)

S. Jonjić & J. Haas
Max von Pettenkofer Institut
Nacionalna zaklada za znanost, visoko obrazovanje i tehnologijski razvoj RH

B. Polić & U. Koszinowski
Max von Pettenkofer Institut
Nacionalna zaklada za znanost, visoko obrazovanje i tehnologijski razvoj RH

B. Polić & A. Porgador
Hebrew University Jerusalem
Cro-Israel joint research program

T. Frančičković & 8 consortium members
EU FP6 INCO

S. Jonjić & J. Haas & F. Čulo
Max von Pettenkofer Institut
Medicinski fakultet Mostar
EU FP6 INCO


S. Volarević & 20 consortium members
EU FP7 CP


S. Jonjić & J. Trgovcich
Ohio State University Columbus
Unity through Knowledge Fund (UKF)

S. Jonjić & O. Mandelboim
Hebrew University Jerusalem
Cro-Israel joint research program

A. Krmpotić
HHMI

Umrežavanje u međunarodnu zajednicu





TransMedRi

Section 1. Scientific and/or technical quality

1.1. Concept and objectives

SWOT ANALYSIS

Weaknesses

1. A negligible number of publications in **highly ranked scientific journals** and a very small number of patents
2. **Criteria for scientific excellence** are not fully developed and implemented
3. Basic and translational research does not meet international criteria, as a result of **insufficient collaboration between different departments**
4. Insufficient research infrastructure and **bio-repositories**
5. The **administrative support** to internationally funded research and technological grants is **inadequate** to serve as a logistical, financial and legal support

TransMedRi

Section 1. Scientific and/or technical quality

1.1. Concept and objectives

SWOT ANALYSIS

Opportunities

1. The European Commission's Seventh Framework programme (FP7) has put emphasis on **translational research** in cancer, infectious diseases and several other areas
2. High quality researchers of Croatian origin are increasingly willing to **return to Croatia** from more developed countries

TransMedRi

Section 1. Scientific and/or technical quality

1.1. Concept and objectives

SWOT ANALYSIS

Threats


1. Relative **shortage of research funding** in Croatia and still inoptimal system of distribution of funds based on scientific excellence;
2. Laboratory consumables and equipment are significantly more **expensive** in Croatia than in the EU
3. University of Rijeka Faculty of Medicine faces **strong competition** from other biomedical research institutions in the South East Europe and wider
4. Many **administrative hurdles** for researchers in Croatia

Science in Croatia faces many problems

- weak mobility
- insufficient funding
- brain drain
- cost of research material and equipment



Jonjić, S., Traven, L. *Nature*, 2004.



■ Price in western countries

■ amount added by local dealers

TransMedRi

Section 1. Scientific and/or technical quality

1.1. Concept and objectives

General aim:

to propose several activities with regards to **training of researchers and upgrading the research infrastructure in order** to enable MEDRI to better integrate into ERA.

Specific aims:

Aim 1. To upgrade the basic and translational **cancer research**

Aim 2. Upgrading the research capacity to study **congenital viral infections**


Aim 3. Upgrading the research capacity in **clinical microbiology**

Aim 4. To upgrade the capacity for translational research in **animal models of human diseases** - In vivo studies on mouse models in translational medicine

TransMedRi

Section 1. Scientific and/or technical quality

iv) A graphical presentation of the components and their interdependencies (Pert diagram)



KOMENTARI EVALUATORA

Kriterij 1: Scientific & Technological Excellence

(max: 5 bodova; prolaz: 3/5)

- Kvaliteta Medicinskog fakulteta Sveučilišta u Rijeci kao cjeline je izvrsna
- Institucija efikasno osigurava financijsku potporu iz domaćih i međunarodnih izvora, uključujući FP i strukturne fondove
- Koncept prijedloga projekta je jasan i uvjerljiv
- SWOT analiza je sveobuhvatna, ciljevi u potpunosti u skladu s identificiranim slabostima institucije: ambiciozni, ali realni
- Sve predviđene projektne aktivnosti su detaljno opisane
- Nedostaje veća povezanost između različitih disciplina – neke prikazane metode su zajedničke pojedinim zavodima te bi se trebale odvijati na razini institucije:
fragmentiranost pristupa dokazuje i podjela radnog plana na radne pakete po pojedinim znanstvenim područjima
- Partnerske organizacije su vrlo dobre kvalitete te pomno izabrane, **ali nedostaje informacija o njihovoj ulozi u projektu**

Ocjena: 4,5


Neki od kriterija izvrsnosti institucije (može se zaključiti):

- Kvaliteta istraživača
- Lista publikacija
- Broj doktoranata i postdoktoranata
- Suradnja s drugim institucijama u regiji i EU
- Iskustvo sudjelovanja u
FP6 i FP7 projektima
- Postojanje strateškog
plana razvoja

TransMedRi

Section 2. Implementation

2.1 Management and organisational structure and procedures



KOMENTARI EVALUATORA

Kriterij 2: Implementation & Management

(max: 5 bodova; prolaz: 3/5)

- Predložena menadžerska struktura i mehanizmi donošenja odluka će definitivno osigurati efikasnu implementaciju projekta
- Znanstvenici s Medicinskog fakulteta u Rijeci imaju potrebne kvalifikacije, što dokazuje i lista objavljenih publikacija (većina je boravila u prestižnim laboratorijima u inozemstvu; imaju razvijenu međunarodnu suradnju)
- Znanstvenici iz inozemstva (“incoming researchers”) koje se planira zaposliti na projektu posjeduju adekvatnu ekspertizu
- Budžet je adekvatan planiranim aktivnostima, detaljan i transparentan
- Pojedine stavke opreme su bazične te ih treba financirati iz drugih izvora
- Ukupni troškovi predviđeni za putovanja su previsoki
- Čini se nepotrebnim zaposliti dva iskusna ekonomista-financijska menadžera

Ocjena: 4,5

KOMENTARI EVALUATORA

Kriterij 3: Potential impact through use of project results

(max: 5 bodova; prolaz: 3/5)

- Ovaj projekt imat će visok učinak na nacionalnom i međunarodnom nivou
- Projekt adresira sve očekivane učinke navedene u Radnom programu
- Projekt ima dobar potencijal da pridonese regionalnom razvoju kroz smanjenje jaza između bazičnih i kliničkih istraživanja te usluga u području javnog zdravstva
- Ostaje nejasno kako će projekt doprinijeti integraciji sveukupnih aktivnosti na Fakultetu
- Diseminacijski plan je kvalitetan

Ocjena: 4,5

Primjer pisma potpore suradnika (od ukupno 19)

TransMedRi

Allgemeines Krankenhaus der Stadt Wien
Klin. Abt. für Nephrologie und Dialyse
Univ. Klinik für Innere Medizin III
Leiter: o. Univ.Prof. DDr. Walter H. Hörl, FRCP



Prof. Dr. Alan Susic, Dean
Faculty of Medicine
University of Rijeka
Brace Branchetta 20
51000 Rijeka
Croatia

Vienna, 7 January 2009

Letter of support to the Faculty of Medicine University of Rijeka for its application to the FP7-REGPOT-2009-1 Call

Dear Professor Susic,


as an Austrian physician trained in Internal Medicine/Nephrology and employed as an assistant professor at the Medical University of Vienna, I would like to express my explicit support for the application of your institution to the above call in frame of FP7. What I understood from the correspondence with Professor Stipan Jonjic, the goal of the project you are applying is to increase the research capacity of your institution with the emphasis on translational medicine.

My group has been collaborating with the group of Professor Stipan Jonjic from the Faculty of Medicine University of Rijeka. Let me provide you with just a few background information: the Department of Nephrology & Transplantation at the Medical University of Vienna is currently treating around 2.500 patients, approximately half of them have been kidney-transplanted within the last 15-20 years, and the other half consists of patients with renal insufficiency. One of the top priority research projects of my group at this moment deals with cytomegalovirus (CMV) infections in immunosuppressed renal transplant patients. This project is truly translational, since we are adding the results of a clinical trial to an in vitro part dealing with HCMV-infected human immune cells and several in vivo/in vitro mouse experiments. The basic idea of our research is following recent clinical observations which have demonstrated the superiority of mTOR inhibitors in preventing CMV-infections, when compared to other forms of immunosuppression.

The expertise of our cooperator Prof. Jonjic and colleagues, who are outstanding experts in the field of viral immunology has been extremely helpful in the planning and conduction of our CMV-experiments. Prof. Jonjic and the facilities of the Faculty of Medicine Rijeka are thus making an important contribution in bringing first hand scientific knowledge from the laboratory bench to the bedside, and our patients are benefiting at the very moment from improved therapies against CMV. It is no exaggeration to report to you that our patients are already profiting from the knowledge we generated, for example we have been able to successfully convert the first kidney/lung-transplant patient with a ganciclovir-resistant CMV infection to an mTOR inhibitor based regimen and achieved full recovery from this patient's CMV-disease. To the best of our knowledge, no such patient has ever been described in the scientific literature world-wide.

Based on the previously mentioned, I strongly believe that such a project will enhance the research potential of your institution as a whole. Needless to say that this will also contribute to strengthening scientific collaboration between my group and the group of Professor Stipan Jonjic. On the long run, I believe that through upgrading research capacity and exchange of knowledge and personnel, this project will bring the quality of research in clinical medicine at your University to a higher level. Since Rijeka is also known as a regional transplantation centre, I can envisage more clinically-oriented future collaboration.

Sincerely,
Marcus Saemann, MD



Ass. Prof. of Nephrology
Medical University of Vienna
Department of Internal Medicine III
Clinical Division of Nephrology and Dialysis
Währinger Gürtel 18-20
A-1090 Wien
tel. +43-1-40400-5593
fax +43-1-40400-7790



Hvala na pažnji!

